Moreover, 18F-FDG PET serves as a diagnostic tool to assess the effectiveness of cancer cell treatment through fibroblast growth factor receptors (FGFR)-targeted therapy, which is activated by FGFR and mTOR/HK2 axis. This evidence concerns the gene HK2 and cancer.